Get the Daily Brief
Latest Biotech News
Regulatory reconsideration for EBV+ PTLD cell therapy
The FDA has agreed to reconsider its January decision to reject Ebvallo (tabelecleucel/tab-cel) for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD),...
Large M&A: Angelini acquires Catalyst for rare neuro drugs
Angelini Pharma agreed to buy Catalyst Pharmaceuticals in a $4.1 billion all-cash deal, aiming to expand its rare neurology portfolio and establish a more direct U.S. commercial presence. The...
Large M&A: Roche acquires PathAI to scale digital pathology
Roche agreed to acquire PathAI for up to $1.05 billion to strengthen its digital pathology capabilities and integrate AI into diagnostics and biopharma workflows. Under the deal terms, Roche will...
Autoimmune IPO: Odyssey Therapeutics raises again after pricing
Odyssey Therapeutics raised about $279 million in its initial public offering, according to company disclosures ahead of Nasdaq trading under the ticker “ODTX.” The autoimmune-focused developer...
CAR-T delivery platform: Vyriad showcases G-Link at ASGCT
Vyriad says it will showcase its modular G-Link CAR-T delivery platform at ASGCT, presenting new options for retargeting lentiviral vectors for in vivo delivery. The protein adapter, developed...
Virology / therapeutics: human measles neutralizing antibodies move toward clinical translation
La Jolla Institute for Immunology (LJI) researchers reported the characterization of human monoclonal antibodies that neutralize measles virus by blocking entry through binding to the virus’s...
Digital pathology consolidation: genomics and AI workflow integration accelerates
Two platform announcements highlighted the next wave of integrated digital health infrastructure for diagnostics and clinical workflows. First, DNAstack and PhenoTips said they integrated their...
Prenatal testing market: BillionToOne reports strong Q1 and prepares Unity Confirm launch
BillionToOne reported that Q1 2026 revenue rose 84% year over year to $108.4 million, driven by growth in its prenatal testing business, and said it expects the Unity Confirm test to expand...
Biotech finance: Tempus raises via convertible notes
Tempus AI announced a private offering of $350 million in convertible senior notes, with net proceeds planned to repay $307.7 million of existing loans and interest while funding other corporate...
Cytometry / diagnostics tooling: Bio-Rad expands antibody conjugation kit portfolio
Bio-Rad expanded its TrailBlazer StarBright Dye Label Kits, providing a broader commercial range for conjugating antibodies to fluorophores via SpyTag and SpyCatcher chemistry. The company said...
FDA pathway reversal for EBV+ PTLD cell therapy Ebvallo
The U.S. FDA agreed to reconsider its earlier shock rejection of Pierre Fabre Pharmaceuticals and Atara Biotherapeutics’ off-the-shelf T-cell therapy Ebvallo (tabelecleucel) after the companies...
Angelini’s $4.1B Catalyst acquisition expands rare neuro portfolio
Italy’s Angelini Pharma agreed to buy Catalyst Pharmaceuticals in an all-cash deal valuing the company at about $4.1 billion, paying $31.50 per share—an approximate 21% premium to the prior close....
Roche’s acquisition of PathAI to scale digital pathology diagnostics
Roche agreed to acquire PathAI in a deal potentially worth up to $1.05 billion, aiming to expand its digital pathology capabilities and accelerate AI-enabled diagnostic workflows. The structure...
Cell therapy manufacturing automation: Cellular Origins teams with Immatics
Cellular Origins agreed to collaborate with Immatics to use the companies’ shared automated manufacturing capabilities, incorporating Cellular Origins’ Constellation mobile robotic platform into...
Big pharma still funding AI diagnostics: Immunai expands AstraZeneca deal to $37.5M
Immunai expanded its collaboration with AstraZeneca to extend usage of its AMICA-OS AI platform across oncology drug development. The parties described the deal as worth up to $37.5 million,...
Tempus convertible notes: $350M funding plan to repay debt and invest
Tempus AI announced plans for a private placement of $350 million in convertible senior notes, with net proceeds intended primarily for debt repayment and funding corporate initiatives. The...
Sarepta revenue holds up, but Elevidys declines and shares slide
Sarepta Therapeutics reported that Elevidys (gene therapy) net product revenue beat Wall Street expectations in its latest quarter, but sales continued to decline as the company navigates ongoing...
BillionToOne expects Unity Confirm to drive more prenatal uptake
BillionToOne told investors it expects its Unity Confirm confirmation test to further differentiate its prenatal genetics suite and increase uptake of its Unity Aneuploidy screening platform. The...
Cancer diagnostics startup Imagenomix raises seed to scale AI histopathology
Imagenomix, an NYU Langone Health spinout building AI-driven cancer diagnostics from standard histopathology images, raised $3.2 million in seed funding. The round was led by Modi Ventures with...
R&D and venture funding: Brano Therapeutics closes $6.8M seed for HFpEF
Singapore-based Brano Therapeutics secured $6.8 million in seed funding to advance new heart failure treatments focused on HFpEF, a condition still marked by limited therapy options. The financing...